Tyra Biosciences, Inc. – NASDAQ:TYRA

Add to watchlist

$10.1

-3.97

-28.22%

Market closed

Open in about 10 hours

-28.98%

month

-28.98%

quarter

+0.50%

year

Market Cap	723.28M
Enterprise value	357.88M

P/E	-10.97
EV/Sales	N/A
EV/EBITDA	-4.42
Price/Sales	N/A
Price/Book	2.35
PEG ratio	-0.10
EPS	-1.68

Revenue	N/A
EBITDA	-87.54M
Income	-75.44M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Tyra Biosciences Stock Forecast

M Q Y

Last Year

$30.4

Potential upside: 200.99%

Analysts Price target
Financials & Ratios estimates

Tyra Biosciences, Inc. (NASDAQ:TYRA): Profit margin
Jun 2023	0	-13.27M
Sep 2023	0	-21.15M
Dec 2023	502K	-22.83M	-4547.81%
Mar 2024	0	-18.19M

Tyra Biosciences, Inc. (NASDAQ:TYRA): Earnings per share (EPS)
2024-03-19	-0.48	-0.53
2024-05-09	-0.46	-0.35

Tyra Biosciences, Inc. (NASDAQ:TYRA): Debt to assets
Jun 2023	250012000	11.44M	4.58%
Sep 2023	238358000	16.18M	6.79%
Dec 2023	225857000	21.59M	9.56%
Mar 2024	404741000	14.86M	3.67%

Tyra Biosciences, Inc. (NASDAQ:TYRA): Cash Flow
Jun 2023	-9.61M	-43K	370K
Sep 2023	-17.14M	-83K	467K
Dec 2023	-13.53M	-144.43M	324K
Mar 2024	-22.02M	18.07M	200.31M

Tyra Biosciences alternative data

Tyra Biosciences, Inc. (NASDAQ:TYRA): Employee count
Aug 2023	38
Sep 2023	38
Oct 2023	38
Nov 2023	38
Dec 2023	38
Jan 2024	38
Feb 2024	38
Mar 2024	49
Apr 2024	49
May 2024	49
Jun 2024	49
Jul 2024	49

Tyra Biosciences
Hedge Funds Holdings Q1 2023

27.08% -56.83%

of TYRA is owned by hedge funds

25 -20

hedge funds hold TYRA stock

11.34M -23.89M

shares is hold by hedge funds

TYRA hedge funds holdings changes

Tyra Biosciences
Insider Trading

Tyra Biosciences, Inc. (NASDAQ:TYRA): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	190806
Jun 2024	0	3702
Sep 2024	0	28554
Oct 2024	9500	232664
Nov 2024	1220681	118916

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	25 Nov 2024	KJELLSON NINA S director director	Common Stock	4,706	$16.84	$79,244
Sale	25 Nov 2024	KJELLSON NINA S director director	Common Stock	566	$16.84	$9,531
Purchase	8 Nov 2024	RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: director, 10 percent owner:	Common Stock	1,220,681	$16.25	$19,836,066
Sale	7 Nov 2024	KJELLSON NINA S director director	Common Stock	19,720	$17.32	$341,511
Sale	7 Nov 2024	KJELLSON NINA S director director	Common Stock	2,371	$17.32	$41,061
Sale	6 Nov 2024	KJELLSON NINA S director director	Common Stock	46,856	$17.18	$804,799
Sale	6 Nov 2024	KJELLSON NINA S director director	Common Stock	5,635	$17.18	$96,787
Sale	5 Nov 2024	KJELLSON NINA S director director	Common Stock	9,367	$16.77	$157,066
Sale	5 Nov 2024	KJELLSON NINA S director director	Common Stock	1,126	$16.77	$18,881
Sale	4 Nov 2024	KJELLSON NINA S director director	Common Stock	960	$17.01	$16,326

TYRA insider trading transactions

Tyra Biosciences
Executives

Insider	Age	Compensation
Dr. Todd Harris Ph.D. (1979) Pres, Chief Executive Officer, Sec., Treasurer & Director	46	$561,330
Mr. Daniel Bensen (1974) Co-Founder & Chief Operating Officer	51	$374,440
Dr. Ronald V. Swanson Ph.D. (1963) Chief Scientific Officer	62	$358,720

Tyra Biosciences
Latest News

Sunday, 17 November 2024
08:15	Post-Election Insider Buying in These 6 Stocks Is Huge	247wallst.com
Wednesday, 13 November 2024
16:05	Tyra Biosciences to Present at Upcoming Investor Conferences	prnewswire.com
Thursday, 7 November 2024
16:05	Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights	prnewswire.com
Monday, 28 October 2024
07:00	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)	prnewswire.com
Friday, 25 October 2024
11:34	Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?	benzinga.com
Thursday, 24 October 2024
18:21	Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)	prnewswire.com
Wednesday, 23 October 2024
16:05	Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET	prnewswire.com
Monday, 21 October 2024
07:55	Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point	seekingalpha.com
Friday, 18 October 2024
14:34	BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug	benzinga.com
Friday, 11 October 2024
08:00	Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)	prnewswire.com
Thursday, 12 September 2024
11:00	The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation	accesswire.com
Wednesday, 11 September 2024
16:05	Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference	prnewswire.com
04:00	Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation	accesswire.com
Tuesday, 10 September 2024
16:05	Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer	prnewswire.com
11:00	The Schall Law Firm Has Launched An Inquiry Into Tyra Biosciences Inc For Securities Law Violations And Investors Are Urged To Contribute	accesswire.com
Monday, 9 September 2024
11:00	Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate	accesswire.com
10:56	Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet	zacks.com
Saturday, 7 September 2024
11:00	Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm	accesswire.com
Friday, 6 September 2024
11:00	Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations	accesswire.com
Thursday, 5 September 2024
11:00	Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join	accesswire.com
Wednesday, 4 September 2024
11:00	The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Possible Securities Related Infractions And Stockholders Can Assist	accesswire.com
Monday, 2 September 2024
11:00	Tyra Biosciences Inc Stockholders Can Partake In An Inquiry Into Whether The Company Defrauded The Public	accesswire.com
Sunday, 1 September 2024
11:00	Attention Investors: The Schall Law Firm Is Looking Into Tyra Biosciences Inc. For Potentially Violating Securities Laws And Investors Can Reach Out	accesswire.com
Saturday, 31 August 2024
11:00	An Inquiry Is Being Made Into Whether Tyra Biosciences Has Defrauded The Public And The Schall Law Firm Wants Shareholders To Help	accesswire.com
Friday, 30 August 2024
11:00	Tyra Biosciences May Have Broken Securities Laws And Impacted Stakeholders Are Urged To Lend A Hand To The Schall Law Firm's Inquiry	accesswire.com
Thursday, 29 August 2024
11:00	The Public Is Encouraged To Reach Out To The Schall Law Firm About An Inquiry Into Tyra Biosciences Inc.'s Potentially Fraudulent Actions	accesswire.com
Wednesday, 28 August 2024
11:00	The Schall Law Firm Invites Investors In Tyra Biosciences Inc To Partake In An Investigation Into Securities Fraud	accesswire.com
Tuesday, 27 August 2024
11:00	An Inquiry Has Been Opened Into Tyra Biosciences Inc's Possible Securities Related Impropriety And Impacted Stakeholders Should Join	accesswire.com
07:00	TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Shareholders to Contact the Firm Today!	accesswire.com
Monday, 26 August 2024
11:00	Tyra Biosciences Inc Is Being Investigated For Possible Securities Law Violations And The Schall Law Firm Seeks Shareholder Involvement	accesswire.com

Ideas & Opinions

Seeking Alpha 29 Aug 2023

Tyra Biosciences: FDA ODD Designation Progresses TYRA-300
Seeking Alpha 19 Sep 2021

U.S. IPO Weekly Recap: The Fall IPO Market Is In Full Swing With An 11 IPO Week

Frequently Asked Questions (FAQ)

What's the price of Tyra Biosciences stock today?

One share of Tyra Biosciences stock can currently be purchased for approximately $10.1.
When is Tyra Biosciences's next earnings date?

Unfortunately, Tyra Biosciences's (TYRA) next earnings date is currently unknown.
Does Tyra Biosciences pay dividends?

No, Tyra Biosciences does not pay dividends.
How much money does Tyra Biosciences make?

Tyra Biosciences has a market capitalization of 723.28M. Tyra Biosciences made a loss 69.13M US dollars in net income (profit) last year or -$0.35 on an earnings per share basis.
What is Tyra Biosciences's stock symbol?

Tyra Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "TYRA".
What is Tyra Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Tyra Biosciences?

Shares of Tyra Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Tyra Biosciences's key executives?
Tyra Biosciences's management team includes the following people:
- Dr. Todd Harris Ph.D. Pres, Chief Executive Officer, Sec., Treasurer & Director(age: 46, pay: $561,330)
- Mr. Daniel Bensen Co-Founder & Chief Operating Officer(age: 51, pay: $374,440)
- Dr. Ronald V. Swanson Ph.D. Chief Scientific Officer(age: 62, pay: $358,720)
Is Tyra Biosciences founder-led company?

Yes, Tyra Biosciences is a company led by its founder Mr. Daniel Bensen.
How many employees does Tyra Biosciences have?

As Jul 2024, Tyra Biosciences employs 49 workers.
When Tyra Biosciences went public?

Tyra Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 15 Sep 2021.
What is Tyra Biosciences's official website?

The official website for Tyra Biosciences is tyra.bio.
Where are Tyra Biosciences's headquarters?

Tyra Biosciences is headquartered at 2656 State Street, Carlsbad, CA.
How can i contact Tyra Biosciences?

Tyra Biosciences's mailing address is 2656 State Street, Carlsbad, CA and company can be reached via phone at +61 97284760.
What is Tyra Biosciences stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Tyra Biosciences in the last 12 months, the avarage price target is $30.4. The average price target represents a 200.99% change from the last price of $10.1.

Tyra Biosciences, Inc.

tyra.bio

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

+61 97284760

2656 State Street
Carlsbad, CA 92008

CIK: 0001863127
ISIN: US90240B1061
CUSIP: 90240B106